137 related articles for article (PubMed ID: 11784835)
1. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change.
Ngan ET; Lane CJ; Ruth TJ; Liddle PF
J Neurol Neurosurg Psychiatry; 2002 Jan; 72(1):106-10. PubMed ID: 11784835
[TBL] [Abstract][Full Text] [Related]
2. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
[TBL] [Abstract][Full Text] [Related]
3. Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study.
Berman I; Merson A; Sison C; Allan E; Schaefer C; Loberboym M; Losonczy MF
Psychopharmacol Bull; 1996; 32(1):95-100. PubMed ID: 8927682
[TBL] [Abstract][Full Text] [Related]
4. Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia.
Lane CJ; Ngan ET; Yatham LN; Ruth TJ; Liddle PF
J Psychiatry Neurosci; 2004 Jan; 29(1):30-7. PubMed ID: 14719048
[TBL] [Abstract][Full Text] [Related]
5. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
[TBL] [Abstract][Full Text] [Related]
6. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia.
Honey GD; Bullmore ET; Soni W; Varatheesan M; Williams SC; Sharma T
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13432-7. PubMed ID: 10557338
[TBL] [Abstract][Full Text] [Related]
7. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.
Molina V; Taboada D; Aragüés M; Hernández JA; Sanz-Fuentenebro J
Schizophr Res; 2014 Sep; 158(1-3):223-9. PubMed ID: 25088730
[TBL] [Abstract][Full Text] [Related]
8. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus.
Liddle PF; Lane CJ; Ngan ET
Br J Psychiatry; 2000 Nov; 177():402-7. PubMed ID: 11059992
[TBL] [Abstract][Full Text] [Related]
9. Cerebral metabolism and risperidone treatment in schizophrenia.
Molina V; Gispert JD; Reig S; Sanz J; Pascau J; Santos A; Palomo T; Desco M
Schizophr Res; 2003 Mar; 60(1):1-7. PubMed ID: 12505132
[TBL] [Abstract][Full Text] [Related]
10. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).
Szulc A; Galinska B; Tarasow E; Dzienis W; Kubas B; Konarzewska B; Walecki J; Alathiaki AS; Czernikiewicz A
Pharmacopsychiatry; 2005 Sep; 38(5):214-9. PubMed ID: 16189748
[TBL] [Abstract][Full Text] [Related]
11. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.
Goghari VM; Smith GN; Honer WG; Kopala LC; Thornton AE; Su W; Macewan GW; Lang DJ
Schizophr Res; 2013 Sep; 149(1-3):149-55. PubMed ID: 23830856
[TBL] [Abstract][Full Text] [Related]
12. Early effects of treatment on regional cerebral blood flow in first episode schizophrenia patients evaluated with 99Tc-ECD-SPECT.
Novak B; Milcinski M; Grmek M; Kocmur M
Neuro Endocrinol Lett; 2005 Dec; 26(6):685-9. PubMed ID: 16380684
[TBL] [Abstract][Full Text] [Related]
13. The resting and activation issue of hypofrontality: a single photon emission computed tomography study in neuroleptic-naive and neuroleptic-free schizophrenic female patients.
Parellada E; Catafau AM; Bernardo M; Lomeña F; Catarineu S; González-Monclús E
Biol Psychiatry; 1998 Oct; 44(8):787-90. PubMed ID: 9798085
[TBL] [Abstract][Full Text] [Related]
14. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.
Bartlett EJ; Wolkin A; Brodie JD; Laska EM; Wolf AP; Sanfilipo M
Psychiatry Res; 1991 Oct; 40(2):115-24. PubMed ID: 1763142
[TBL] [Abstract][Full Text] [Related]
15. Neuroleptic effects on regional brain metabolism in first episode schizophrenics.
Cleghorn JM; Szechtman H; Garnett ES; Brown GM; Nahmias C; Szechtman B; Kaplan R; Franco S
Schizophr Res; 1991 Oct; 5(3):208-9. PubMed ID: 1684720
[No Abstract] [Full Text] [Related]
16. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
[TBL] [Abstract][Full Text] [Related]
18. Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia.
Molina V; Reig S; Pascau J; Sanz J; Sarramea F; Gispert JD; Luque R; Benito C; Palomo T; Desco M
Psychiatry Res; 2003 Nov; 124(3):163-75. PubMed ID: 14623068
[TBL] [Abstract][Full Text] [Related]
19. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.
Mateos JJ; Lomeña F; Parellada E; Mireia F; Fernandez-Egea E; Pavia J; Prats A; Pons F; Bernardo M
Psychopharmacology (Berl); 2007 Apr; 191(3):805-11. PubMed ID: 17019564
[TBL] [Abstract][Full Text] [Related]
20. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
Reimold M; Solbach C; Noda S; Schaefer JE; Bartels M; Beneke M; Machulla HJ; Bares R; Glaser T; Wormstall H
Psychopharmacology (Berl); 2007 Feb; 190(2):241-9. PubMed ID: 17111172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
